electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company focused on improving health through its non-invasive vagus nerve stimulation (nVNS) technology platform and related product offerings. The Company’s portfolio also includes Quell, a wearable, app and cloud-enabled neuromodulation platform that is indicated for the treatment of fibromyalgia symptoms and lower-extremity chronic pain. Its product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headaches, and handheld, personal use consumer products. Its products include gammaCore, Quell Fibromyalgia, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com.
高成長
同社の収益は過去3年間にわたり着実に増加しており、年平均で99.83%の成長率を示しています。
成長中
同社は成長フェーズにあり、最新の年間収益はUSD 32.03Mに達しています。
適正水準
同社の最新のPEは-3.44で、過去3年間の水準と比較して適正圏にあります。
機関投資家の売り越し
最新の機関投資家の保有株数は923.46K株で、前四半期比で26.43%減少しています。
ジェームズ・シモンズが保有
スター投資家ジェームズ・シモンズは本銘柄を0.00株保有しています。
市場活動が低調
同社への投資家の関心は低下しており、20日間の売買回転率は-0.24です。